Evidence map›Paper›PMID 39997456›Full record

ReviewJournal of fungi (Basel, Switzerland)2025

Antifungal Policy and Practice Across Five Countries: A Qualitative Review.

David W Denning, John R Perfect, Neda Milevska-Kostova, Artes Haderi, Hannah Armstrong, Maarten C Hardenberg, Emily Chavez, Bruce Altevogt, Patrick Holmes, Jalal A Aram

Abstract readReview
In one paragraph

Review in Journal of fungi (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David W DenningManchester Fungal Infection Group, The University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PL, UK.ORCID 0000-0001-5626-2251
John R PerfectDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0002-8742-3676
Neda Milevska-KostovaDepartment of Medical Microbiology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.ORCID 0000-0003-1596-9036
Artes HaderiCharles River Associates, London EC2M 7EA, UK.ORCID 0000-0002-5753-5642
Hannah ArmstrongCharles River Associates, London EC2M 7EA, UK.ORCID 0009-0005-9799-2927
Maarten C HardenbergCharles River Associates, London EC2M 7EA, UK.
Emily ChavezPfizer Inc., New York, NY 10001, USA.
Bruce AltevogtBiomerieux, 100 Rue Louis Pasteur, 69280 Marcy-l'Étoile, France.ORCID 0009-0004-8608-0597
Patrick HolmesPfizer Inc., New York, NY 10001, USA.
Jalal A AramMelinta Therapeutics, Parsippany, NJ 07054, USA.ORCID 0000-0001-5184-1182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The burden of invasive fungal infections (IFIs) is increasing worldwide. National, regional, and local policies on IFI management should respond to the changing landscape. We assessed antifungal policies from five countries of varying size, IFI burden, and geography: the Netherlands, Italy, South Korea, China, and India. These countries were selected as a representative sample reflecting different types of economic and health systems that patients and providers access worldwide. This assessment focused on a comprehensive range of antifungal policy elements, including recognition and prioritization, awareness and education, prevention and monitoring, diagnosis and coordinated care, access to appropriate treatment, and diagnostic and treatment innovation. Although countries in this analysis all have some form of policy for IFI management, we have identified substantial gaps, including low prioritization of IFI diagnostics, omission of fungal pathogens from antimicrobial resistance policies, and a general lack of awareness and healthcare professional (HCP) training on IFI management. The gaps identified are intended to inform HCPs and policy- and decision-makers about aspects to consider in reducing the IFI burden for patients and health systems while demonstrating responsible antifungal stewardship.

Indexed as

educationinvasive fungal infectionspolicystewardshipsurveillance

Identifiers

PMID39997456
PMCPMC11856614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.